SIONNA THERAPEUTICS INC
SIONNASDAQ🏆 #3611 by market capEarnings Nov 3US Equity
$192.95▲ $13.10 (+6.79%)
Simulated priceTrack SION
Get earnings, price moves & breaking news on Telegram
24h▲ 6.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$231M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
80
Good
No chart data available for SION.
Trading Snapshot
- Day Range
- $191.10 – $195.62
- 52-Week Range
- $4.01 – $54.97
- Volume
- $2.32B
- Avg Volume
- $2.16B
- Shares Outstanding
- 45.2M
- Next Earnings
- Oct 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $22M
- Last Q Revenue
- $6M
- P/E Ratio
- -2.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.16
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −9.4%
Why Investors Own SION
- ✓High-growth profile — revenue up +46.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SIONNA THERAPEUTICS INC
SIONFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$89M▲ +26.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$67M▲ +26.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.0M▼ −9.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$50M▲ +$22M YoY
StockOtter · stockotter.spaceAbout SIONNA THERAPEUTICS INC
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100
Analyst Price Target
ⓘAverage Target
$202.90
▲ +5.2% Upside
High Target$224.32
Low Target$166.41
Based on 14 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
SIONNA THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift SION price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
SIONNA THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.